Are you one of the many Massachusetts residents whose life has been transformed by GLP-1 drugs, only to now face the possibility of losing access to them? This is the part most people miss: Starting January 1st, major health insurers like Blue Cross Blue Shield of Massachusetts and Point32Health will no longer cover these weight-loss medications, leaving many in a difficult position. While these drugs have been a game-changer for those struggling with obesity, their high cost has sparked a heated debate about accessibility and insurance coverage.
But here's where it gets controversial: Insurers are giving large employers the option to pay extra to continue covering GLP-1s for their workers. This raises questions about equity—will only employees of wealthier companies retain access to these life-altering treatments? And what does this mean for individuals who rely on these drugs but work for smaller businesses or are self-employed?
Now that open enrollment for health insurance is underway, The Boston Globe wants to hear from workers whose employers have chosen not to cover GLP-1s anymore. Have you been using these medications to manage your weight, only to find out your employer is dropping coverage? Are you grappling with what to do next? Your story matters, and we want to amplify it.
Fill out the survey below, and a reporter may reach out to you. This is your chance to share your experience and shed light on an issue that affects countless others. But here’s the real question: Should access to life-changing medications like GLP-1s be determined by your employer’s budget, or is this a responsibility that falls squarely on insurers and policymakers? Let us know what you think in the comments—we’re eager to hear your perspective.
Jonathan Saltzman can be reached at jonathan.saltzman@globe.com.
